BARD1 PRESENTING AT BELL POTTER
HEALTHCARE CONFERENCE
onlyMelbourne, Australia, 10 November 2021: BARD1 Life Sciences Limited (ASX:BD1) (BARD1 or the
Company) is pleased to announce that BARD1 CEO Dr Leearne Hinch will be delivering the enclosed presentation to the Bell Potter Healthcare Conference today.
Authorised by the Company Secretary, Tony Di Pietro.
- ENDS -
use | |
COMPANY CONTACTS | |
Dr Leearne Hinch | Dr Geoff Cumming |
CEO | Non-executive Chairman |
E leearne@bard1.com | Egeoff.cumming@bard1.com |
M +61 400 414 416 | M +61 417 203 021 |
ABOUT BARD1 LIFE SCIENCES LTD
BARD1 Life Sciences Ltd (ASX:BD1) (BARD1 or the Company) is an Australian diagnostics company personalwith an innovative portfolio of diagnostic technologies and products. The Company is focused on developing and commercialising diagnostic solutions for healthcare professionals and patients. BARD1 has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NETpan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes tests in development for ovarian and breast cancers, and research-stage projects for prostate and
pancreatic cancers. For more information on BARD1, see www.bard1.comand www.exo-net.com.
FORWARD LOOKING STATEMENTS
This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward- looking words such as 'may', 'should', 'expect', 'anticipate', 'estimate', 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements. For
BARD1 Life Sciences Limited (ABN 58 009 070 384) | 23 Normanby Road, Notting Hill VIC 3168
P +61 3 95487586 | | Einfo@bard1.com| Wwww.bard1.com
For personal use only
Detecting cancer earlier to save lives
Bell Potter Healthcare Conference 10 November 2021
Leearne Hinch | CEO
BARD1 Life Sciences Ltd (ASX:BD1) www.bard1.com| info@bard1.com
For personal use only
Disclaimer
This presentation has been prepared by BARD1 Life Sciences Limited ("BARD1" or the "Company") based on information available to it as at the date of this presentation. This presentation contains general and background information about the Company's activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the information that an investor should consider when making an investment decision and does not contain all information about the Company's assets and liabilities, financial position and performance, profits and losses, prospects, and the rights and liabilities attaching to the Company's securities necessary to make an investment decision. The information in this presentation should be read in conjunction with the Company's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange (ASX), available at www.asx.com.au. The information in this presentation is based on the Company's own information and estimates and has not been independently verified. The Company is not responsible for providing updated information and assumes no responsibility to do so. Any investment in the Company should be considered speculative and there is no guarantee that they will make a return on capital invested, that dividends would be paid, or that there will be an increase in the value of the investment in the future.
This Presentation may contain certain "forward-looking statements" that are based on management's beliefs, assumptions and expectations and on information currently available to management. The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Any indications of, and guidance on, future operating performance, earnings, financial position and performance are also forward- looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions.
Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including BARD1 or any of its advisers). In particular, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward-looking statements in this Presentation will actually occur. Actual operations, results, performance, targets or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based.
Nothing contained in this Presentation constitutes investment, legal, tax or other advice. This Presentation does not purport to be all inclusive or to contain all information which its recipients may require in order to make an informed assessment of the Company's prospects.
You should note that any past performance is given for illustrative purposes only and should not be relied on as (and is not) an indication of the Company's views on its future financial performance or condition. Past performance, including past share price performance, of BARD1 cannot be relied on as an indicator of (and provides no guidance as to) future performance including future share price performance.
BARD1 Presentation November 2021 Page 2
only
Company overview
BARD1 Life Sciences (ASX: BD1)
• | Diagnostics company focused on earlier detection of cancer |
• | Game-changing technologies with multiple applications |
BARD1 History
2016 BARD1 AAb technology acquired
2020 SubB2M and EXO-NET® technologies acquired / in-licensed
use
• Strong pipeline for breast, ovarian, prostate & other cancer diagnostics | |
targeting US$11b global markets | |
• | Compelling POC results for lead SubB2M tests for breast & ovarian cancers1 |
• | Strong cash position to commercialise lead products as LDTs |
2021
SubB2M proof-of-concept results for breast and ovarian cancers
RUO EXO-NET exosome capture tool launched
For personal
• Products in-market for bladder cancer2 & exosome research |
Board and management
Dr Geoff Cumming | Dr Leearne Hinch |
Chairman | Chief Executive Officer |
Max Johnston | Dr Greg Rice |
Non-Exec Director | Chief Scientific Officer |
Phillip Powell | Tony Di Pietro |
Non-Exec Director | CFO / Company Sec |
Prof Allan Cripps | Dr Wayne Jensen |
Non-Exec Director | R&D Director |
Dr Emily Stein | |
Technology Director (NETs) |
Financial information (ASX:BD1) | |
Ordinary shares | 91,934,920 |
Share price (9/11/21) | A$0.985 |
Market capitalisation | A$90.6m |
Cash position (30/9/21) | A$20.4m |
Ave monthly cash burn (Q1 FY22) | A$593k |
Share price performance (Past 12 months)
Dx = Diagnostics; POC = Proof of Concept;; LDT = Laboratory Developed Test; | BARD1 Presentation November 2021 Page 3 |
1 SubB2M proof-of-concept data using SPR; 2 Adjunct to urine cytology to assist the detection of bladder cancer |
For personal use only
Global cancer diagnostics market
- Global cancer burden: 50.6m people, 19.3m new cases and 10.0m deaths p.a.1
- Global cancer diagnostics market valued at US$250b2
- BARD1 is targeting markets worth US$11b for some of the world's most common and deadliest cancers
# | Cancer | Prevalence | Incidence | Deaths | |
1 | Breast | 1 | 7,790,717 | 2,261,419 | 684,996 |
3 | 4,956,901 | 1,414,259 | 375,304 | ||
Prostate | |||||
17 | Ovarian | 823,315 | 313,959 | 207,252 | |
22 | Pancreatic | 379,958 | 495,773 | 466,003 | |
Breast Cancer3 | Pancreatic Cancer6 |
US$4.2b |
US$2.4b
4 | Prostate Cancer5 |
Ovarian Cancer | US$3.3b |
US$1.8b | |
1 GLOBOCAN (IARC) 2020;2 Grand View Research 2019. https://www.grandviewresearch.com/press-release/global-cancer-diagnostics-market;3 https://www.grandviewresearch.com/industry-analysis/breast- | BARD1 Presentation November 2021 | Page 4 |
cancer-diagnostics-market;4 https://www.grandviewresearch.com/industry-analysis/ovarian-cancer-diagnostics-market;5https://www.grandviewresearch.com/industry-analysis/prostate-cancer-diagnostics- | ||
market;6 https://www.wboc.com/story/43615802/pancreatic-cancer-diagnostic-market-size-2021-with-a-cagr-of-69-top-companies-data-report-covers-market-specific-challenges-brief-analysis-and |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
BARD1 Life Sciences Ltd. published this content on 10 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 November 2021 01:14:06 UTC.